Nanatinostat + Valganciclovir/Pembrolizumab for Nasopharyngeal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a combination of nanatinostat, valganciclovir, and pembrolizumab in patients with certain EBV-related cancers. Nanatinostat makes cancer cells more vulnerable, allowing valganciclovir to kill them, while pembrolizumab boosts the immune system to fight the cancer.
Who Is on the Research Team?
Darrel P Cohen, MD, PhD
Principal Investigator
Viracta Therapeutics
Are You a Good Fit for This Trial?
This trial is for adults with advanced EBV+ solid tumors, including nasopharyngeal carcinoma, who've tried at least one platinum-based chemotherapy but no more than three treatments. They must have measurable disease and be in good physical condition (ECOG 0 or 1), with proper bone marrow and liver function.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1b Dose Escalation
Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week, and valganciclovir starting at 900 mg orally daily to evaluate safety and determine the recommended Phase 2 dose
Phase 1b Cohort
Patients with other EBV+ solid tumors receive nanatinostat in combination with valganciclovir at the RP2D
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nanatinostat
- Pembrolizumab
- Valganciclovir
Find a Clinic Near You
Who Is Running the Clinical Trial?
Viracta Therapeutics, Inc.
Lead Sponsor